Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | IL1B | P01584 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1595322 | 1.00 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1594760 | 0.92 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1595582 | 0.92 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1595483 | 0.87 | KDM4E (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1594821 | 0.87 | KDM4E (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL178031 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL14127685 | 0.87 | IL1B (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL14127738 | 0.87 | IL1B (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL178134 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7898226 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | claimed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | claimed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | claimed |
| US-7919503-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | claimed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | claimed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | claimed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7919503-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | disclosed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | ALDH1A1 1830/4885NPC1 1162/4885RAB9A 3807/4885 |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | ALDH1A1 1830/4885NPC1 1162/4885RAB9A 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.